Application Note

Cell Line Development: Accelerating Antibody Discovery With The Octet® Platform

Source: Sartorius

By Hongshan Li


Cell line development involves multiple processes. Large numbers of clones are screened and selected on the basis of productivity and stability. Octet® systems have been an established platform for rapid titer of antibody clones to enable quick selection of high-producing clones. Combined with the Octet® Sialic Acid (GlyS) and Octet® Mannose (GlyM) kit assays, cell line development scientists can also screen for the relative terminal sialic acid content in crude or purified samples to better select optimal clones that are both high producers and have desirable sialic acid content.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online